How do Trulicity and Ozempic work?
Trulicity (dulaglutide) and Ozempic (semaglutide) are both injectable GLP-1 receptor agonists that mimic the hormone GLP-1 to boost insulin release, slow gastric emptying, and reduce appetite for blood sugar control in type 2 diabetes. Trulicity is a long-acting GLP-1/GIP agonist given weekly via a prefilled pen. Ozempic is a GLP-1 agonist also given weekly but targets slightly different receptor pathways, leading to stronger weight loss effects in studies.[1]
What conditions are they approved for?
Both treat type 2 diabetes alongside diet and exercise. Ozempic has additional FDA approvals for reducing cardiovascular risk in patients with type 2 diabetes and heart disease, and for chronic weight management (at higher doses as Wegovy, a related brand). Trulicity is approved for cardiovascular risk reduction but lacks a specific weight loss indication.[1][2]
How do dosing and administration differ?
Trulicity starts at 0.75 mg weekly, titrating up to 4.5 mg. Ozempic starts at 0.25 mg weekly, up to 2 mg. Both use auto-injector pens for once-weekly subcutaneous shots, typically in the abdomen, thigh, or upper arm. Ozempic pens allow more flexible dose adjustments.[1]
What do trials show for blood sugar control and weight loss?
In head-to-head trials like SUSTAIN FORWARD, Ozempic (1 mg) reduced A1C by 1.5% vs. Trulicity's (1.5 mg) 1.4% after 40 weeks, with Ozempic users losing more weight (8.6 lb vs. 6.5 lb). Both lowered cardiovascular events similarly in larger outcomes trials (REWIND for Trulicity, SUSTAIN-6 for Ozempic).[3]
Side effects and safety profile
Common side effects overlap: nausea (20-40% for both), vomiting, diarrhea, and injection-site reactions. Ozempic reports slightly higher GI issues and a black-box warning for thyroid tumors (rodent data). Trulicity has similar warnings but fewer gallbladder-related reports. Both carry risks of pancreatitis and hypoglycemia when combined with insulin.[1][2]
Cost and insurance coverage
Without insurance, a month's supply costs $900-$1,000 for both. Copays vary; Ozempic often has stronger manufacturer coupons. Medicare Part D covers both, but prior authorizations are common for off-label use.[4]
Who makes them and when do patents expire?
Eli Lilly makes Trulicity (U.S. patents expire 2028-2033, facing challenges).[5] Novo Nordisk makes Ozempic (patents to 2032, with biosimilar litigation ongoing).[5] Check DrugPatentWatch.com for latest expiry and litigation updates: Trulicity patents, Ozempic patents.
[1] FDA labels: Trulicity, Ozempic
[2] ADA Standards of Care 2024
[3] Diabetes Care 2020;73(5):958-967 (SUSTAIN FORWARD trial)
[4] GoodRx pricing data, Oct 2024
[5] DrugPatentWatch.com